.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,816,404

« Back to Dashboard

Claims for Patent: 7,816,404

Title:Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions
Abstract: A highly water soluble ferric pyrophosphate citrate chelate useful for treating iron deficiency contains 2% or less phosphate by weight. These chelate compositions are easily milled and/or processed into dosage forms using conventional techniques, and are expected to exhibit advantageous biocompatibility as compared to conventional soluble ferric pyrophosphates, ferric salts, ferric polysaccharide complexes and ferrous salts.
Inventor(s): McCall, Jr.; William S. (Raleigh, NC)
Assignee: Rockwell Medical Technologies, Inc. (Wixom, MI)
Application Number:12/138,018
Patent Claims: 1. A water-soluble solid ferric pyrophosphate citrate chelate composition comprising: iron citrate pyrophosphate; and phosphate in an amount of 2% or less by weight.

2. The composition of claim 1, wherein iron is present in an amount of 7% to 11% by weight, citrate is present in an amount of from 14% to 30% by weight, and pyrophosphate is present in an amount of from 10% to 20% by weight.

3. The composition of claim 1, which is soluble in water in an amount of at least 1 gram per milliliter of water.

4. The composition of claim 1, wherein phosphate is present in an amount of 1.5% or less by weight.

5. The composition of claim 1, wherein phosphate is present in an amount of 1% or less by weight.

6. The composition of claim 1, wherein phosphate is present in an amount of 0.1% or less by weight.

7. A process for preparing a water-soluble solid ferric pyrophosphate citrate chelate composition comprising: combining a citrate ion source, a pyrophosphate ion source, and a ferric ion source in water to form a solution; adding an organic solvent in a volume sufficient to precipitate a solid ferric pyrophosphate citrate chelate composition from the resulting solution; and isolating the solid ferric pyrophosphate citrate chelate composition, said chelate composition having 2% or less phosphate by weight.

8. The process of claim 7, wherein the solid ferric pyrophosphate chelate composition has iron present in an amount of 7% to 11% by weight, citrate is present in an amount of from 14% to 30% by weight, and pyrophosphate is present in an amount of from 10% to 20% by weight.

9. The process of claim 7, wherein the amount of citrate ion source, pyrophosphate ion source, and ferric ion source are selected so that the molar ratio of ferric ion:citrate ion:pyrophosphate ion is 0.9 to 1.1:0.9 to 1:1:0.45 to 0.55.

10. The process of claim 7, wherein the amount of citrate ion source, pyrophosphate ion source, and ferric ion source each contain less than 250 micrograms of the metals aluminum, antimony, arsenic, bismuth, cadmium, copper, lead, mercury, molybdenum, thallium, and tin per gram of the ion source.

11. The process of claim 7, wherein the pyrophosphate ion source contains less than 0.1% phosphate.

12. The process of claim 7, wherein the pyrophosphate ion source contains less than 0.01% phosphate.

13. The process of claim 7, wherein the amount of said water used to dissolve the citrate ion source, the pyrophosphate ion source and the ferric ion source is from 1.5 milliliters to 10 milliliters for each gram of ferric ion source.

14. The process of claim 7, wherein said solution is heated to a temperature of from 70.degree. C. to 85.degree. C. before the ferric ion source is added and maintained at a temperature of from 70.degree. C. to 85.degree. C. after the ferric ion source is added and until complete dissolution of the ferric ion source has occurred.

15. The process of claim 14, wherein after the ferric ion source has completely dissolved, the temperature of the solution is lowered to a range of from 15.degree. C. to 75.degree. C. to prevent hydrolysis of pyrophosphate.

16. The process of claim 7, wherein the organic solvent is selected from methanol, ethanol, propanol, 2-propanol, acetonitrile, acetone, 2-butanone, and combinations of these solvents.

17. The process of claim 7, wherein the organic solvent is added to the solution containing the dissolved ferric ion source, the dissolved citrate ion source and the dissolved pyrophosphate ion source in an amount of from 10 to 25 milliliters per gram of the ferric ion source.

18. The process of claim 7, wherein the solid ferric pyrophosphate citrate chelate is dried at a temperature of 80.degree. C. or less.

19. The process of claim 7, wherein the ferric ion source is selected from ferric sulfate, ferric sulfate hydrate, ferric chloride, ferric ammonium sulfate, and combinations of these materials; the citrate ion source is selected from citric acid, monosodium citrate, disodium citrate, trisodium citrate, and combinations of these materials; and the pyrophosphate ion source is selected from disodium dihydrogen pyrophosphate, tetrasodium pyrophosphate, and a combination of both of these materials.

20. A pharmaceutical composition comprising: an oral or parenteral dosage form containing a therapeutically effective amount of a solid ferric pyrophosphate citrate chelate composition having 2% or less phosphate by weight.

21. The composition of claim 20, which is a dialysate.

22. A process for treating iron deficiency comprising: administering to a subject in need of treatment for iron deficiency, a pharmaceutical composition comprising an oral or parenteral dosage from containing a therapeutically effective amount of a solid ferric pyrophosphate citrate chelate composition having 2% or less phosphate by weight.

23. The process of claim 22, in which administration is via dialysis.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc